

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RUI KANG PHARMACEUTICAL GROUP INVESTMENTS LIMITED

銳康藥業集團投資有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

CHANGE OF AUDITOR

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Rui Kang Pharmaceutical Group Investments Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.50(4) of the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”).

The Board announces that after careful consideration of a number of factors including the professional risk associated with the audit and the level of audit fee, HLB Hodgson Impey Cheng Limited (“**HLB**”) has resigned as auditor of the Company with effect from 3 November 2017.

HLB has confirmed that there are no other matters in connection with its resignation that needs to be brought to the attention of the shareholders or creditors of the Company. The Board and audit committee of the Company have confirmed that there are no disagreement or unresolved matters between the Company and HLB, and that there are no matters or circumstances in respect of the change of the auditor which should be brought to the attention of shareholders of the Company.

The Board further announces that, with the recommendation of the audit committee of the Board, RSM Hong Kong has been appointed as the new auditor of the Company with effect from 3 November 2017 to fill the causal vacancy following the resignation of HLB and to hold office until conclusion of the forthcoming annual general meeting of the Company.

The Board would like to take this opportunity to express its sincere gratitude to HLB for its professional services rendered to the Group in the past year.

By order of the Board
Rui Kang Pharmaceutical Group Investments Limited
LIU Xiaolin
Chairman and Executive Director

Hong Kong, 3 November 2017

As of the date of this announcement, the executive Directors are Mr. LIU Xiaolin (Chairman), Mr. LEUNG Pak Hou Anson and Mr. WANG Zheng; the non-executive Director is Mr. HUANG Song and the independent non-executive Directors are Mr. YAN Guoxiang, Mr. LEUNG Ka Fai and Mr. HO Fung Shan Bob.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and on the website of the Company at www.ruikang.com.hk.